Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0087111,
umls-concept:C0205265,
umls-concept:C0229789,
umls-concept:C0302592,
umls-concept:C0337112,
umls-concept:C0355642,
umls-concept:C0441769,
umls-concept:C0445202,
umls-concept:C0457152,
umls-concept:C0677582,
umls-concept:C1274040,
umls-concept:C1514695,
umls-concept:C1522449,
umls-concept:C1524075,
umls-concept:C1555582
|
pubmed:issue |
3
|
pubmed:dateCreated |
1990-11-20
|
pubmed:abstractText |
From November 1979 to October 1986, 367 patients were entered onto RTOG 7920 and randomized to receive either pelvic irradiation alone or pelvic plus para-aortic radiation. Patients with Stage IIB cervical carcinoma who had not undergone curative surgery and patients with Stages IB and IIA cervical carcinoma who were determined by digital exam to have primary tumors measuring 4 cm or greater in lateral dimension were eligible for this study. Clinically apparent or surgically involved para-aortic nodes were reason for exclusion from the study. Pelvic irradiation consisted of 1.6-1.8 Gy per day for 5 days per week to a total of 40-50 Gy. Para-aortic irradiation delivered 44 to 45 Gy in 1.6-1.8 Gy per day, 5 days per week. Pelvic irradiation was to be completed in 4 1/2 to 6 1/2 weeks and para-aortic irradiation in 4 1/2 to 5 1/2 weeks. Intracavitary brachytherapy delivered a total of 4000-5000 mg hr of radium-equivalents or 30-40 Gy to point A. Patients were stratified prior to random treatment assignment by histology, para-aortic nodal status (negative vs. unevaluated), and FIGO stage. As of June 1, 1989, 30 cases were excluded, including five patients who were inevaluable. Two patients who refused the assigned treatment were also excluded. Therefore, a total of 330 cases were analyzable. At 5 years the estimates of survival, the primary endpoint, for the pelvic only and pelvic plus para-aortic irradiation arms are 55% and 65%, respectively (p = 0.043). Several secondary endpoints were also analyzed. Estimates for loco-regional control at 5 years are, for pelvic irradiation only, 66%, and for pelvic plus para-aortic irradiation, 75% (p = 0.21). Distant metastases are estimated in 32% of pelvic irradiation only patients and 25% of pelvic plus para-aortic irradiation patients at 5 years (p = 0.17). When the first disease failure patterns are examined, more patients fail distally when treated only with pelvic radiation than when using pelvic plus para-aortic fields (p = .04). In analysis of patients with grade 3 (severe), grade 4 (life-threatening), and grade 5 (fatal complications), 8% of the patients in both groups had grade 3 severe complications. In the pelvic plus para-aortic group, 11 patients had grade 4 and 2 had grade 5 complications, whereas 6 had grade 4 and none had grade 5 in the pelvic only treatment group.(ABSTRACT TRUNCATED AT 400 WORDS)
|
pubmed:grant | |
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0360-3016
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
513-21
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:2211198-Adenocarcinoma,
pubmed-meshheading:2211198-Adult,
pubmed-meshheading:2211198-Aged,
pubmed-meshheading:2211198-Aged, 80 and over,
pubmed-meshheading:2211198-Brachytherapy,
pubmed-meshheading:2211198-Carcinoma, Squamous Cell,
pubmed-meshheading:2211198-Female,
pubmed-meshheading:2211198-Humans,
pubmed-meshheading:2211198-Lymph Nodes,
pubmed-meshheading:2211198-Lymphatic Irradiation,
pubmed-meshheading:2211198-Middle Aged,
pubmed-meshheading:2211198-Pelvic Neoplasms,
pubmed-meshheading:2211198-Survival Rate,
pubmed-meshheading:2211198-Uterine Cervical Neoplasms
|
pubmed:year |
1990
|
pubmed:articleTitle |
Prophylactic irradiation of the para-aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920.
|
pubmed:affiliation |
State University of New York, Health Science Center, Brooklyn 11203.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|